Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | KDM1A | O60341 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9969547 | 0.87 | HDAC1 (0.61) | NOTUMHDAC1CYP19A1NPC1RAB9A | |
| SCHEMBL12885309 | 0.87 | NOTUM (0.73) | NOTUMHDAC1CYP19A1NPC1RAB9A | |
| SCHEMBL6980467 | 0.85 | NOTUM (1.00) | NOTUMHDAC1CYP19A1 | |
| SCHEMBL2820279 | 0.84 | NOTUM (0.69) | NOTUMHDAC1CYP19A1NPC1RAB9A | |
| SCHEMBL16206205 | 0.83 | NOTUM (0.73) | NOTUMHDAC1CYP19A1KDM1A | |
| SCHEMBL15803296 | 0.83 | CYP19A1 (0.56) | NOTUMHDAC1CYP19A1NPC1RAB9A | |
| SCHEMBL2494737 | 0.83 | NOTUM (0.73) | NOTUMHDAC1CYP19A1NPC1RAB9A | |
| SCHEMBL2819423 | 0.83 | NOTUM (0.68) | NOTUMHDAC1CYP19A1 | |
| SCHEMBL15803295 | 0.81 | HDAC1 (0.58) | NOTUMHDAC1CYP19A1NPC1RAB9A | |
| SCHEMBL28863788 | 0.81 | NOTUM (0.71) | NOTUMCYP19A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-20150307475-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-20150259305-A1 | CATALYTIC REACTION | NATIONAL TSING HUA UNIVERSITY (TW) | 2015-09-17 | — | — | US | disclosed |
| US-20150259305-A1 | CATALYTIC REACTION | NATIONAL TSING HUA UNIVERSITY (TW) | 2015-09-17 | — | — | US | disclosed |
| US-20140171404-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
| WO-2010071813-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α | ARYX THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307475-A1 | Autotaxin inhibitors | ENPP2, ATXN10, ATXN2L | NOTUM 2658/4885HDAC1 1497/4885CYP19A1 3901/4885 |
| US-20150259305-A1 | CATALYTIC REACTION | HAO2, CAT, HAAO | NOTUM 1479/4885HDAC1 2575/4885CYP19A1 358/4885 |
| US-20140171404-A1 | Autotaxin inhibitors | ENPP2, ATXN10, ATXN2L | NOTUM 2777/4885HDAC1 1983/4885CYP19A1 4766/4885 |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | NOTUM 815/4885HDAC1 1167/4885CYP19A1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.